Wave Life Sciences Shares Move Higher On Therapeutic Pact With GSK Targeting Genetic Disorders

  • Wave Life Sciences Ltd WVE and GSK plc GSK have announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing program targeting alpha-1 antitrypsin deficiency, WVE-006. 
  • The discovery collaboration has an initial four-year research term. 
  • The collaboration includes two main components. The first is a discovery collaboration that enables GSK to advance up to eight programs and Wave to advance up to three programs. 
  • In addition to these programs, GSK receives the exclusive global license for Wave's preclinical program, WVE-006.
  • Wave will receive an upfront payment of $170 million, including $120 million in cash and a $50 million equity investment.
  • For the WVE-006 program, Wave is eligible to receive up to $225 million in development and launch milestones, up to $300 million in sales-related milestone payments, and tiered sales royalties. 
  • Development and commercialization responsibilities will transfer to GSK after Wave completes the first-in-patient study.
  • For each of GSK's eight collaboration programs, Wave will be eligible to receive up to $130-$175 million in development and launch milestones and $200 million in sales-related milestones, along with tiered sales royalties. 
  • Price Action: WVE shares are up 21.9% at $4.40 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechLarge CapNewsPenny StocksHealth CareContractsSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!